Key Financial Figures - Standalone (in ₹ lakhs)
Income Statement:
- Revenue from operations: 8,842.73 (Q1 FY27) vs 6,563.51 (Q1 FY26) - 34.7% increase
- Other income: 45.71 (Q1 FY27) vs 74.11 (Q1 FY26)
- Total Income: 8,888.44 (Q1 FY27) vs 6,637.62 (Q1 FY26)
Expenses Breakdown:
- Cost of materials consumed: 4,847.25
- Purchase of Stock-in-trade: 294.39
- Changes in inventories: -25.24
- Employees benefits expenses: 1,692.64
- Finance costs: 446.56
- Depreciation and amortization: 278.22
- Other expenses: 1,238.52
- Total Expense: 8,772.34
Profitability:
- Profit before tax: 116.10 (Q1 FY27) vs 32.31 (Q1 FY26) - 259% increase
- Tax Expense: Nil current tax, Nil deferred tax
- Net Profit for the period: 116.10 (Q1 FY27) vs 32.31 (Q1 FY26)
- Other Comprehensive Income: 0.00
- Total Comprehensive income: 116.10
Capital Structure:
- Paid up Equity Share Capital (Face value ₹10): 1,592.09
- Other Equity: 8,817.82
- Earnings per share (Basic & Diluted): ₹0.73 (Q1 FY27) vs ₹0.20 (Q1 FY26)
Key Financial Figures - Consolidated (in ₹ lakhs)
Income Statement:
- Revenue from operations: 8,861.61 (Q1 FY27) vs 6,587.09 (Q1 FY26)
- Other income: 43.82 (Q1 FY27) vs 72.22 (Q1 FY26)
- Total Income: 8,905.43 (Q1 FY27) vs 6,659.31 (Q1 FY26)
Profitability:
- Profit before tax: 113.77 (Q1 FY27) vs 20.85 (Q1 FY26)
- Tax Expense: Nil current tax, Nil deferred tax
- Net Profit for the period: 113.77 (Q1 FY27) vs 20.85 (Q1 FY26)
- Profit attributable to equity holders of parent: 112.35
- Profit attributable to non-controlling interest: 1.42
- Earnings per share (Basic & Diluted): ₹0.71
Subsidiary Information
The consolidated results include the following subsidiaries:
- Lifezen Health Care Private Limited
- Balance Clinics LLP
- Bal Research Foundation
- Aurum Research & Analytical Solutions Private Limited
Subsidiaries contributed total income of ₹38.23 lakhs and net loss of ₹2.33 lakhs for the period ended June 30, 2026.
Approval and Dates
- Financial results reviewed by Audit Committee and approved by Board of Directors
- Board meeting held on August 12, 2026 (commenced at 04:45 PM, concluded at 05:15 PM)
- Results prepared in accordance with Indian Accounting Standard 34 (Ind AS 34)
- The company has only one reportable segment: 'Pharmaceuticals'